Live Breaking News & Updates on Ongoing Research May Lead
Stay updated with breaking news from Ongoing research may lead. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings of MANIFEST-2 show “valuable evidence that the addition of pelabresib offers meaningful improvements over JAK inhibitor monotherapy as a first-line approach for patients with myelofibrosis,” according to one expert.